Home › Calculator › AMGN Dividend Calculator 2026
AMGN Dividend DRIP Calculator 2026
2.44% YieldHealthcareAmgen Inc. · NASDAQ
Price: $407.44 · Annual div: $9.94/share · Frequency: quarterly · Payout ratio: 70% · Ex-div: 2026-08-21
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When AMGN pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your AMGN snowball 📈
$10,000 in AMGN → $31.0K in 10 years · $53.76/month
About Amgen Inc. (AMGN) — Dividend Analysis 2026
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Compare AMGN with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full AMGN DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open AMGN position with:
🌍 AMGN Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold AMGN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.44% | -0.36% | $244 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.07% | -0.73% | $207 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.95% | -0.85% | $195 / yr |
| 🇬🇧 UK ISA | 0% | 2.44% | -0.36% | $244 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.23% | -0.57% | $223 / yr |
| 🇨🇦 TFSA | 0% | 2.44% | -0.36% | $244 / yr |
| 🇨🇦 CA Taxable | 25% | 1.83% | -0.97% | $183 / yr |
| 🇦🇺 Super (pension) | 15% | 2.07% | -0.73% | $207 / yr |
| 🇦🇺 AU Taxable | 30% | 1.71% | -1.09% | $171 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.80% | -1.00% | $180 / yr |
| 🇫🇷 FR Taxable | 30% | 1.71% | -1.09% | $171 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 AMGN Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $9.94/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 AMGN Dividend Payment Schedule
AMGN pays quarterly — 4 times per year. Ex-div: 2026-08-21.
📊 AMGN vs Healthcare Benchmarks
How AMGN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AMGN sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ AMGN Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Other | 2027-08-07 | 17,201 | $410.95 | $7.07M | ||
| M-Exempt | 2026-08-13 | 1,252 | $162.60 | $203.6K | ||
| Sale | 2026-08-13 | 1,252 | $416.43 | $521.4K | ||
| Sale | 2026-08-11 | 2,000 | $412.57 | $825.1K | ||
| M-Exempt | 2026-08-13 | 1,252 | $162.60 | $203.6K | ||
| A-Award | 2026-08-07 | 730 | — | — | ||
| A-Award | 2026-08-07 | 85.169 | — | — | ||
| A-Award | 2026-08-07 | 103.419 | — | — | ||
| A-Award | 2026-08-07 | 63.876 | — | — | ||
| M-Exempt | 2026-08-06 | 2,069 | $162.60 | $336.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare AMGN with peers: AMGN vs ABBV · AMGN vs AZN · AMGN vs BMY
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where AMGN earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AMGN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Amgen Inc. (AMGN) is currently trading at $407.44, 9% below its 52-week high. The current dividend yield is 2.44% based on an annual payout of $9.94 per share.
Amgen Offers Solid Dividend Growth Supported by Stable Healthcare Cash Flows
AI SummaryAmgen Inc. presents a compelling profile for income-focused investors within the healthcare sector. Trading at $413.08 with a market capitalization of $222.9 billion, the company offers an annual dividend of $9.94, translating to a yield of 2.41%. Its conservative payout ratio of 70% ensures that shareholder distributions remain well-covered by earnings, reinforcing dividend safety and leaving adequate capital for operational reinvestment and debt management. The firm demonstrates a strong dividend growth trajectory, underpinned by a 5-year dividend CAGR of 8.2%. While its P/E ratio of 29.0 suggests a premium valuation, Amgen's reliable cash flow generation supports the sustainability of its current yield. Overall, the company balances attractive income growth with manageable payout level
- Patent expirations on key biologic drugs threatening revenue growth
- Pricing pressures and regulatory scrutiny within the biopharmaceutical industry
Generated by AI using live market data. For educational purposes only — not financial advice.
Latest AMGN News
LiveHow investors use the AMGN dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.